MediciNova's MN-001 (tipelukast) Hits HDL Endpoints but Misses Significance on Triglycerides at Week 24 in Phase 2 NAFLD Trial
核心洞察
MediciNova reported topline results from the Phase 2 MN-001-NATG-202 trial of MN-001 (tipelukast) in 40 patients with NAFLD and hypertriglyceridemia (搜索) associated with type 2 diabetes.
MN-001 produced a statistically significant 30.96 mg/dL greater reduction in serum triglycerides than placebo at Week 4 (p=0.015), but the Week 24 difference of 31.4 mg/dL was not significant (p=0.113).
HDL cholesterol rose 3.3 mg/dL with MN-001 versus a 2.4 mg/dL decline on placebo at Week 24, a significant 5.7 mg/dL between-group difference (p=0.0048).
MediciNova has reported topline results from MN-001-NATG-202, a Phase 2 randomized, double-blind, placebo-controlled trial of MN-001 (tipelukast) in 40 patients with nonalcoholic fatty liver disease (搜索) (NAFLD) and hypertriglyceridemia (搜索) associated with type 2 diabetes mellitus (搜索) (T2DM). The 24-week study met its lipid-related exploratory endpoints on HDL measures and showed an early, statistically significant triglyceride effect, while liver fat and body weight moved in a favorable direction without reaching significance.
Triglycerides: Early Signal, Later Attenuation
At Week 4, mean serum triglycerides fell from baseline by 54.7 mg/dL (26.05%) in the MN-001 group and by 23.8 mg/dL (11.54%) in the placebo group, a 30.96 mg/dL greater reduction for MN-001 that was statistically significant (p=0.015).
At Week 24, the between-group difference was no longer statistically significant. Mean serum triglycerides decreased by 45.8 mg/dL (21.78%) with MN-001 versus 14.4 mg/dL (6.97%) with placebo, a 31.4 mg/dL greater mean decrease (p=0.113). MediciNova noted that the MN-001 group continued to show a numerical reduction from baseline at Week 24.
HDL Cholesterol and Particle Concentration Reach Significance
The strongest statistical findings were on HDL parameters. At Week 24, mean HDL cholesterol increased by 3.3 mg/dL (8.39%) in the MN-001 group while decreasing by 2.4 mg/dL (6.23%) in the placebo group, a 5.7 mg/dL between-group difference (p=0.0048).
Mean HDL particle concentration (HDL-P) rose by 3.62 µmol/L (11.80%) with MN-001 and fell by 0.9 µmol/L (3.00%) with placebo, a 4.52 µmol/L difference (p=0.018).
Liver Fat and Body Weight Trend Favorably
Liver fat was assessed by controlled attenuation parameter (CAP) score using FibroScan. At Week 24, mean CAP decreased by 14.1 dB/m (4.24%) in the MN-001 group and by 4.3 dB/m (1.27%) in the placebo group, a 9.7 dB/m greater mean decrease that was not statistically significant (p=0.2438).
Mean body weight decreased by 4.91 lb (2.28%) with MN-001 and by 0.55 lb (0.25%) with placebo at the end of the study, a 4.36 lb greater mean decrease (p=0.082).
Safety Profile
MN-001 was generally safe and well tolerated. Treatment-related adverse events were mild to moderate in severity, and no drug-related serious adverse events were reported in the study.
Mechanism and Prior Data
MN-001 is an orally bioavailable small-molecule compound. In preclinical models it is thought to act through leukotriene receptor antagonism, inhibition of phosphodiesterase (搜索) (mainly 3 and 4), and inhibition of 5-lipoxygenase (搜索) (5-LO). The 5-LO/LT pathway has been postulated as a pathogenic factor in fibrosis development. MN-001 has been shown to down-regulate expression of fibrosis-promoting genes including LOXL2, Collagen Type 1 and TIMP-1, and inflammation-promoting genes including CCR2 and MCP-1. It also inhibits triglyceride synthesis in hepatocytes by inhibiting arachidonic acid uptake. Recent research suggested that MN-002, the major metabolite of MN-001, enhanced cholesterol efflux in macrophages by upregulating the transport proteins ABCA1 (搜索) and ABCG1 (搜索).
MediciNova stated that the changes in triglycerides, HDL-C and HDL-P were consistent with preclinical in-vitro mechanism of action studies and with the earlier MN-001-NATG-201 clinical trial.
Next Steps
MediciNova characterized MN-001-NATG-202 as a proof-of-concept, exploratory study in 40 patients. The company said preliminary review of the topline data indicates efficacy should be evaluated in a larger study, and that it will continue detailed analyses and assess the next stage of clinical development, including appropriate patient population, endpoints and sample size.
MN-001 was previously evaluated in a Phase 2 trial in idiopathic pulmonary fibrosis (搜索), and a second Phase 2 trial in NAFLD is ongoing. MediciNova's pipeline is built on two compounds, MN-166 (ibudilast) and MN-001, with 11 programs in clinical development. MN-166 is in Phase 3 for amyotrophic lateral sclerosis (搜索) and degenerative cervical myelopathy and is Phase 3-ready for progressive multiple sclerosis (搜索), and is also being evaluated in Phase 2 trials in Long COVID and substance dependence.
Disease Context
T2DM is a metabolic disorder characterized by insulin resistance, which plays a central role in the development of dyslipidemia (搜索). Hypertriglyceridemia (搜索) is commonly observed in people with T2DM and results from increased hepatic lipid synthesis and impaired clearance of triglyceride-rich lipoproteins. Hypercholesterolemia, particularly elevated LDL cholesterol and reduced HDL cholesterol, is also frequently seen and contributes to a higher risk of atherosclerosis. Dyslipidemia worsens glycemic control and increases the risk of cardiovascular complications and liver-related conditions such as NAFLD, which is considered a hepatic complication of insulin resistance and is frequently associated with T2DM and dyslipidemia.